Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-Analysis

Authors

  • wang xin Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • yang hui Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • zhang xiaodong Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • cui xiangli Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • wang shihui Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • liu lihong Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

DOI:

https://doi.org/10.18433/J3805B

Abstract

Objectives: Valganciclovir 900 mg/day is approved for cytomegalovirus (CMV) prophylaxis, but 450 mg/day is seems also effective. We systematically reviewed the efficacy and safety of low-dose versus high-dose valganciclovir prophylaxis in renal transplantation recipients. Methods: An electronic search was conducted up to November 29, 2016. The primary outcomes were incidences of CMV, CMV disease, mortality and opportunistic infection. The second outcomes were acute rejection, allograft loss, adverse drug reaction (ADR). Results: 7 cohort studies, all with high quality involving (1431 patients) were included. There was no significant difference of the incidence of following CMV disease (1271 patients, odds ratio [OR] 0.74, 95% confidence interval [CI], 0.38-1.43, p=0.36), acute rejection (1343 patients, OR 0.77, 95%CI 0.53-1.14, p=0.19), allograft loss (1271 patients, OR 0.64, 95%CI 0.31-1.35, p=0.24), mortality (1271 patients, OR 0.55, 95%CI 0.20-1.47, p=0.23) and opportunistic infections (OI) (985 patients, OR 0.76, 95%CI 0.52-1.10, p=0.14) between the low-dose and the high-dose valganciclovir  prophylaxis. And no significant difference was observed for premature valganciclovir discontinuation (1010 patients, OR 0.81, 95%CI 0.52-1.25, p=0.33) and the incidence of leukopenia (1082 patients, OR 0.65, 95%CI 0.34-1.22, p=0.18) between the two regimens. Conclusion: 450 mg and 900 mg doses of valganciclovir are equipotent for CMV universal prophylaxis. CMV 450 mg prophylaxis should be used for renal transplant recipients.

 

This article is open to POST-PUBLICATION REVIEW. Registered readers (see “For Readers”) may comment by clicking on ABSTRACT on the issue’s contents page.

Downloads

Download data is not yet available.

Downloads

Published

2017-07-26

How to Cite

xin, wang, hui, yang, xiaodong, zhang, xiangli, cui, shihui, wang, & lihong, liu. (2017). Effectiveness of Valganciclovir 900mg Versus 450mg for Cytomegalovirus Prophylaxis in Renal Transplantation: A Systematic Review and Meta-Analysis. Journal of Pharmacy & Pharmaceutical Sciences, 20, 168–183. https://doi.org/10.18433/J3805B

Issue

Vol. 20 (2017): Pages 168-318 and 20s-140s

Section

Systematic Review and Meta-Analysis

License

This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.

CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.